2021 Volume No 41 pages 431-453
Title: IL-1β-pre-conditioned mesenchymal stem/stromal cells’ secretome modulates the inflammatory response and aggrecan deposition in intervertebral disc |
Authors: JR Ferreira, GQ Teixeira, E Neto, C Ribeiro-Machado, AM Silva, J Caldeira,
C Leite Pereira, S Bidarra, AF Maia, M Lamghari, MA Barbosa, RM Gonçalves |
Address: I3S – Rua Alfredo Allen 208, 4200-135 Porto,
Portugal |
E-mail: raquelg at ineb.up.pt |
Abstract: Mesenchymal stem/stromal cells (MSCs) have been increasingly used in clinical trials for low-back pain
(LBP) and intervertebral disc (IVD) degeneration with promising results. Their action mechanisms are not
fully understood, but they reduce IVD pro-inflammatory markers in a pro-inflammatory/degenerative IVD
microenvironment. In this study the therapeutic potential of the MSC secretome, as an alternative cell-free
approach for treating degenerated IVDs, was examined. Human bone marrow-derived MSC secretome
(MSCsec) was collected after 48 h of preconditioning in IL-1β (10 ng/mL) and low oxygen (6 % O2), mimicking
the degenerative IVD. IL-1β-pre-conditioning of MSCs increased secretion of pro-inflammatory markers hIL-6,
hIL-8, hMCP-1, etc. The therapeutic effect of MSCsec was tested in a pro-inflammatory/degenerative IVD ex
vivo model. MSCsec down-regulated IVD gene expression of pro-inflammatory cytokines (bIL-6, bIL-8) and
matrix degrading enzyme bMMP1, while bMMP3 and bTIMP2 were up-regulated, at 48 h. After 14 d, MSCsec-treated IVDs revealed increased aggrecan deposition, although no differences in other ECM components were
observed. Protein analysis of the MSCsec-treated IVD supernatant revealed a significant increase of CXCL1,
MCP-1, MIP-3α, IL-6, IL-8 and GRO α/β/γ (related to TNF, NOD-like receptor and neutrophil chemotaxis
signalling), and a decrease of IFN-γ, IL-10, IL-4, IL-5 and TNF-α (associated with T-cell receptor signalling).
MSCsec-treated IVD supernatants did not promote angiogenesis and neurogenesis in vitro. Overall, MSCsec
can be a safe therapeutic approach, presenting a strong immunomodulatory role in degenerated IVD while
potentiating aggrecan deposition, which can open new perspectives on the use of MSCsec as a cell-based/
cell-free therapeutic approach to LBP. |
Key Words: Mesenchymal stem cells, degenerative intervertebral discs, immunomodulation, secretome,
paracrine signalling, extracellular matrix. |
Publication date: April 20th 2021 |
Article download: Pages
431-453 (PDF file) |